EXACT Therapeutics AS: Notice of extraordinary general meeting

03 Dec 2024 14:23 CET

Oslo, 3 December 2024: Reference is made to the stock exchange announcements
published yesterday and earlier today regarding by EXACT Therapeutics AS'
("EXACT-Tx" or the "Company") successful placement of 31,182,795 new shares for
total gross proceeds of NOK 145 million, of which 21,558,645 shares shall be
issued in tranche 2, together with 13,364,041 non-tradeable warrants. For the
purpose of issuing the tranche 2 shares and the warrants, an extraordinary
general meeting of the Company will be held as a virtual meeting on Tuesday 17
December 2024 at 10:30 CET. In addition, the board proposes certain other
resolutions, as included in the notice.

The notice for the extraordinary general meeting, including the attendance and
proxy forms, is attached to this announcement. The documents are also available
at www.exact-tx.com. The deadline for receiving proxies or attendance
registration is 13 December 2024 at 16:00 CET.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

633752_EXACT Therapeutics - EGM Notice 2024.pdf